Boston Scientific priced a public offering of $1.85 billion aggregate principal amount of its senior notes. The public offering consists of $600 million of 2.85 percent notes due May 15, 2020; $500 million of 3.375 percent notes due May 15, 2022 and $750 million of 3.85 percent notes due May 15, 2025.
EndoChoice filed for a $115 million initial public offering, according to an Atlanta Business Chronicle report. The proceeds of the IPO would be used to fund the commercialization of the c company’s Fuse endoscopy system.
Cahaba Government Benefit Administrators approved reimbursement of EndoGastric Solutions‘ Transoral Incisionless Fundoplication procedure.
GI Dynamics‘ ongoing clinical trial of EndoBarrier Therapy was placed on hold, preventing further enrollment, by the FDA. The decision to hold further enrollment is due to the fact that there have been four cases of hepatic abscess among the 325 subjects currently enrolled in the ENDO Trial.
Nineteen analysts have given Salix Pharmaceuticals stock a consensus price target of $142.19, according to a Sleek Money report.
If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.
More articles on gastroenterology:
Dr. David Bernstein named PAION medical advisor
FDA clears 3 GI devices in April
4 statistics on GI physician career satisfaction
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
